Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | GAA | P10253 | 2/20 | 0.78 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.68 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1988224 | 1.00 | ALDH1A1 (0.81) | ALDH1A1LMNAGAAUSP2TSHR | |
| SCHEMBL1902263 | 0.98 | ALDH1A1 (0.85) | ALDH1A1LMNAGAAUSP2TSHR | |
| SCHEMBL10445162 | 0.98 | ALDH1A1 (0.85) | ALDH1A1LMNAGAAUSP2TSHR | |
| SCHEMBL14470279 | 0.95 | ALDH1A1 (0.75) | ALDH1A1LMNAGAAUSP2TSHR | |
| SCHEMBL2300296 | 0.94 | ALDH1A1 (0.73) | ALDH1A1LMNAGAAUSP2TSHR | |
| SCHEMBL3830424 | 0.91 | POLB (0.80) | ALDH1A1LMNAGAATSHRPOLB | |
| SCHEMBL7122592 | 0.91 | POLB (0.80) | ALDH1A1LMNAGAATSHRPOLB | |
| SCHEMBL735657 | 0.91 | POLB (0.80) | ALDH1A1LMNAGAATSHRPOLB | |
| SCHEMBL5407453 | 0.88 | ALDH1A1 (1.00) | ALDH1A1LMNAGAAUSP2TSHR | |
| Isothiocyanate SCHEMBL6156518 | 0.87 | ALDH1A1 (0.70) | ALDH1A1LMNAGAAUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | BIOGEN, INC. | 2004-07-08 | — | — | US | claimed |
| US-6630503-B1 | Non-peptidic sulfonamide compounds that specifically inhibit the binding of ligands to VLA-4 for inhibition, prevention and suppression of VLA-4-mediated cell adhesion and pathologies such as inflammation and immune reactions | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | VCAM1, ICAM1, EPCAM | ALDH1A1 631/4885LMNA 875/4885GAA 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.